Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity - Wikidata - wikimedia - TriplyDB

Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity

Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity

http://www.wikidata.org/entity/Q33617472

about

Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders Genetically engineered mouse models of Parkinson's disease Neurogenic bowel dysfunction in patients with spinal cord injury, myelomeningocele, multiple sclerosis and Parkinson's disease Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model Vesicular integrity in Parkinson's disease Mice genetically depleted of brain serotonin display social impairments, communication deficits and repetitive behaviors: possible relevance to autism Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson's Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein Expression The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons.Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: behavioral and neurochemical studies in the rat.Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis.Behavioral phenotyping of mouse models of Parkinson's disease.Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions.Neuroscience and heart-brain medicine: the year in review.Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?Fungal-derived semiochemical 1-octen-3-ol disrupts dopamine packaging and causes neurodegeneration Inducible dopaminergic glutathione depletion in an α-synuclein transgenic mouse model results in age-related olfactory dysfunction.Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease.A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease.VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.Vivo-morpholinos induced transient knockdown of physical activity related proteins.Intact olfaction in a mouse model of multiple system atrophy.Non-motor and motor features in LRRK2 transgenic mice.Noradrenaline and Parkinson's disease.Olfaction in three genetic and two MPTP-induced Parkinson's disease mouse models.Chronic amitriptyline treatment attenuates nigrostriatal degeneration and significantly alters trophic support in a rat model of parkinsonism Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases.Monoamine reuptake inhibitors in Parkinson's disease.Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity Industrial toxicants and Parkinson's disease.Monoamine transporters: vulnerable and vital doorkeepers.Sleep disturbances in Alzheimer's and Parkinson's diseases.Comparative Proteomic Analysis of Carbonylated Proteins from the Striatum and Cortex of Pesticide-Treated Mice.α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits Retinal dopamine mediates multiple dimensions of light-adapted vision.

P2860

Q26826093-633D134E-C3F6-48CF-9293-4AE74AA19C92 Q26852964-679198F0-8F9F-4F72-94C2-05B17D9E2E66 Q27012533-78BA1A87-A26C-4F4E-B0F7-C4FB3F25DF25 Q27330366-563D7E3F-D11B-4FF0-AF65-80C3E5280244 Q28384426-4FDFEDBC-BA5C-4B51-9F09-B0853F25C5A9 Q28385737-88A6BF78-ADB0-4FE6-ADAD-F1283308C611 Q28390641-0BD9B627-B0D9-42C5-93C7-08CDCE51E1CD Q28511558-149107AD-48EC-43A0-B95A-E16BF0C19CAF Q30359033-C1F6EF82-C407-4177-8E6A-5627D1BF2A45 Q30430534-56D57167-0A2C-4816-9C3C-0251440CF86D Q30487373-07349ADD-EE34-4B68-90AD-B636114AD16D Q33671819-67C8A1A0-A080-4650-B3D3-2CEC4344269E Q33724885-307CD05D-7D35-43A8-B921-2E3509D8532F Q33778472-7171D0C3-41AA-46A9-BCC3-99C105028B5B Q33820609-1C626D4E-DA42-4390-B025-64F729D77BDD Q33882719-9685648C-4813-4FF1-A5D9-5FBEAE7ED594 Q33896138-B4EE327C-0839-4B26-A8EA-C29A753A71EA Q34094065-40DF52E6-D569-42F1-B47E-F7F2B713B306 Q34182826-87A4CB3F-FF97-4BBB-83DA-6BB2BB26343F Q34307633-08A7502B-8F63-4FDF-B9C8-D3027635E345 Q34384338-E034673C-E093-4902-A272-8348E8706AFA Q34441722-DCA07252-989E-4147-8C80-2314C46E7638 Q34482196-87434B05-7CF6-41C4-A550-A4BC16F95AE2 Q34560077-BE47AD5A-5E81-4E36-A120-173959AAEC76 Q34595165-9DC7B38C-CADD-4FA5-91CF-1FB987B76F70 Q34695522-60B65ACD-3C53-4414-8F9A-863F5FA15BC3 Q34732028-AA15BA86-DEDA-4FD8-93CC-6B19AAFD4796 Q34922393-1486C2A7-C78D-4657-ADAD-C6A9A4458146 Q35013240-870BBB49-3F11-481C-8514-E2E147DEC5DC Q35035322-F86E3A67-BD0A-45E4-913D-E26E25606C92 Q35089378-7509FDED-BCDD-4821-AB8E-949380FDFF0C Q35142854-D5B0DCD6-4B36-4006-865A-8DDED510DDCC Q35165280-0DCE9B23-9387-4982-9656-77A9761CADEB Q35810975-EED9778C-AF41-4B89-A44F-80CE4FC5DA33 Q35822952-28045045-C750-4E8A-81B3-7F1D690A1691 Q35877150-E14CF524-9847-40AE-BE02-9B46FE3953C8 Q35981780-263E77F2-524C-4622-84EB-7F155F6715DB Q35988085-25DD68C4-B661-4615-B60A-00359B2B4956 Q36034871-A930133F-5F11-4369-BF25-DBB6B6205916 Q36104677-FA7598B0-C678-42D0-924B-1279882A1BA7

P2860

Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity

http://www.wikidata.org/entity/Q33617472

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity

@ast

Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity

@en

type

label

Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity

@ast

Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity

@en

prefLabel

Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity

@ast

Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity

@en

P1433

Q33617472-781F5817-CFC1-4E98-ABD2-2A237791FD9B

P1476

Q33617472-343945D8-8439-49DA-A327-42A8B0FB33E9

P2093

Q33617472-07903C31-C9AD-4F76-A1FA-4367408EA831

Q33617472-244AA6CC-84BE-4287-8720-639CAEC62226

Q33617472-6031DA15-32E1-4090-B16C-D5A3228BA819

Q33617472-6DA98B1A-D72C-4F99-BC3A-8D6F5E5EB574

Q33617472-81DABE1F-857F-496A-9FE3-57936E57DB97

Q33617472-85F5E2EA-7372-4830-8239-8274A74745F2

Q33617472-B54EC20B-6029-4D48-82A5-80CEA8360035

Q33617472-C6660DF7-DB1F-45BD-B53F-9AC34B9593EF

Q33617472-DA474EC2-0974-446D-A088-AD01CB6DF5A4

P2860

Q33617472-048593AC-9C24-496A-B920-7FA36EBC8F2B

Q33617472-0AAC3E0C-C73C-469C-9E12-EE62472F3D17

Q33617472-0DB958D4-4A0B-40E0-8950-CA949C14D5C7

Q33617472-0E2E9DD5-1DF0-4B76-B31D-8FCE076AA3AD

Q33617472-12F58D61-7B22-46F1-B135-ADF581DF4A24

Q33617472-1B63972E-C371-4A84-8BE5-B50C69ED4025

Q33617472-2208AAA8-6B61-4798-BF83-86A666115D11

Q33617472-23F44314-7334-4F10-A6FC-C49AEB0C6593

Q33617472-2D32B2D8-1F02-4853-9CFE-6DD3E5E46DC6

Q33617472-2F529568-E1A7-4208-8D8E-5D878BCFBCBF

P304

Q33617472-02EA5302-AD41-4BF9-B276-DFA95E4DA9BB

P31

Q33617472-C5197614-DA02-449C-8DD3-7DABB8B5DC8A

P356

Q33617472-9E64622F-C9BD-4984-9A24-DAD774368735

P407

Q33617472-1B4914F8-5540-4398-B4AD-FFA4A10E56BC

P433

Q33617472-E8BE1FE7-C751-4255-A461-AA8E7879071A

P478

Q33617472-E28CF0C6-9C9B-4DC3-AEAC-0F531013B3A1

P577

Q33617472-0F012E2B-857F-4867-881F-64793EACDDF0

P698

Q33617472-B1C92152-7542-49A6-BAFA-BEA043EAA7F4

P921

Q33617472-0DAE7E04-7541-4B6D-BA74-16A3D5BD3A0F

P932

Q33617472-93B38110-F605-4739-94E9-18020CF84046

P356

JNEUROSCI.1495-09.2009

P1433

Journal of Neuroscience

P1476

Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity

@en

P2093

AliReza Noorian

http://www.w3.org/2001/XMLSchema#string

Chad R Jackson

http://www.w3.org/2001/XMLSchema#string

David Weinshenker

http://www.w3.org/2001/XMLSchema#string

Gary W Miller

http://www.w3.org/2001/XMLSchema#string

James G Greene

http://www.w3.org/2001/XMLSchema#string

Kennie R Shepherd

http://www.w3.org/2001/XMLSchema#string

P Michael Iuvone

http://www.w3.org/2001/XMLSchema#string

Tonya N Taylor

http://www.w3.org/2001/XMLSchema#string

W Michael Caudle

http://www.w3.org/2001/XMLSchema#string

P2860

Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice

Staging of brain pathology related to sporadic Parkinson's disease

Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration

The Parkinson's complex: parkinsonism is just the tip of the iceberg

Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor

Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice

Parkinson's disease: mechanisms and models

Oxidative stress in Parkinson's disease

Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat

Frequency of bowel movements and the future risk of Parkinson's disease.

P304

8103-8113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.1495-09.2009

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19553450

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2813143

http://www.w3.org/2001/XMLSchema#string